InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata Announces Collaboration with Maverick Therapeutics for use of RaDaR™ Assay
Inivata today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the ... Read More
Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
M. Kfoury, C.Bonnet, N.Delanoy, C. Brizais, A. Leformal, K. Howarth, C. Morris, E. Lecerf, A. Leary Read More
World Conference on Lung Cancer 2021
Event expiration date display - 26 - 29 JAN 2021
Location: Singapore Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.
